When entering the specialty pharmaceuticals arena, manufacturers need to evaluate the capabilities of their channel partners carefully
Kent Rogers, Acorda Therapeutics
Advertisement
Articles by Kent Rogers, Acorda Therapeutics
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmaceutical Commerce
1
Why UPS Committed $48M to Cold-Chain Cross-Dock Buildout
2
Payers Want Real-World Evidence. Why Aren't They Using It?
3
Philip Sclafani: Will PBM Reform Actually Lower Net Drug Costs?
4
How the US Section 301 Probe Targets Germany's Drug Pricing
5